References
- Cole J A, Norman H, Doherty M, Walker A M. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. Obstet Gynecol 2007; 109: 339–346
- Scarabin P Y, Oger E, Plu-Bureau G, EStrogen and THromboEmbolism Risk Study Group. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003; 362: 428–432
- Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, Lévesque H, Trillot N, Barrellier M T, Wahl D, Emmerich J, et al. Estrogen and Thromboembolism Risk (ESTHER) Study Group. Hormone therapy and venous thromboembolism among postmenopausal women: impact of estrogen administration and progestagens: the ESTHER study. Circulation 2007; 115: 840–845
- Post M S, Christella M, Thomassen L G, van der Mooren M J, van Baal W M, Rosing J, Kenemans P, Stehouwer C D. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women. Arterioscler Thromb Vasc Biol 2003; 23: 1116–1121
- Straczek C, Oger E, Yonde Jonage-Canonico M B, Plu-Bureau G, Conard J, Meyer G, Alhenc-Gelas M, Lévesque H, Trillot N, Barrellier M T, et al. Estrogen and Thromboembolism Risk (ESTHER) Study Group. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation 2005; 112: 3495–3500
- Slater C C, Hodis H N, Mack W J, Shoupe D, Paulson R J, Stanczyk F Z. Markedly elevated levels of estrone sulfate after long-term oral, but not transdermal, administration of estradiol in postmenopausal women. Menopause 2001; 8: 200–203